Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Summary

ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with ALS.

Timeline

Start

2023-11-09

Primary completion

2024-06-26

Completion

2024-06-26

Publications

• Yeole A, Khanna L, Doshi M, Sharma A, Uttarwar P, Doshi S, Kaushik Kumar R, Venkataramana N, Parmar D. A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2025 Nov;26(7-8):794-801. doi: 10.1080/21678421.2025.2515900. Epub 2025 Jun 13.

Drugs

Indications